H. Lee Moffitt Cancer Center and Research Institute Hospital, INC.

H. Lee Moffitt Cancer Center and Research Institute Hospital, INC. was paid $24.44M by Medicaid between Jan 2018 and Oct 2024, across 329 billing codes. Its largest line is J7050, Infusion, normal saline solution, 250 cc — 12% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	64,549	$1.23M
2019	147,725	$5.58M
2020	157,626	$5.85M
2021	168,222	$5.79M
2022	144,081	$4.67M
2023	29,491	$1.31M
2024incomplete	197	$2K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J7050	Infusion, normal saline solution, 250 cc	12%	18,833	8,850	$2.82M
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	7.1%	48,438	30,072	$1.73M
J9271	Injection, pembrolizumab, 1 mg	7.0%	834	597	$1.71M
77386		6.8%	8,283	804	$1.66M
J2505	Injection, pegfilgrastim, 6 mg	4.0%	1,632	1,049	$972K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	3.9%	20,891	10,598	$954K
J7030	Infusion, normal saline solution , 1000 cc	2.9%	7,823	4,481	$707K
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	2.8%	5,336	2,712	$696K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	2.2%	9,489	8,005	$529K
80053	Comprehensive metabolic panel	2.1%	51,854	29,564	$509K
36415	Collection of venous blood by venipuncture	2.1%	33,884	22,980	$502K
77412		2.0%	3,812	483	$500K

317 more codes

Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	2.0%	577	$492K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	1.8%	1,069	$438K
J9306	Injection, pertuzumab, 1 mg	1.7%	663	$415K
J9299	Injection, nivolumab, 1 mg	1.6%	559	$400K
78815	Positron emission tomography (PET) for limited area imaging	1.6%	2,539	$399K
96415		1.6%	5,285	$385K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	1.5%	986	$361K
77336		1.5%	3,735	$361K
71260	Computed tomography, thorax, diagnostic; with contrast material	1.2%	7,882	$294K
96361	Intravenous infusion, hydration; each additional hour	1.1%	3,830	$280K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	4,058	$244K
36591		<1%	12,107	$238K
96416		<1%	2,988	$236K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	2,703	$227K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	3,409	$213K
96402		<1%	2,249	$203K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	413	$201K
96367		<1%	4,741	$182K
82948		<1%	4,221	$180K
A9576	Injection, gadoteridol, (prohance multipack), per ml	<1%	3,439	$180K
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	6,294	$169K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	52,537	$168K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	1,423	$154K
96375	Therapeutic injection; each additional sequential IV push	<1%	12,434	$142K
38222		<1%	1,103	$141K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	24,470	$139K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	<1%	80	$138K
J0897	Injection, denosumab, 1 mg	<1%	635	$136K
36592		<1%	2,382	$122K
J1453	Injection, fosaprepitant, 1 mg	<1%	3,398	$120K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	2,847	$119K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	5,934	$117K
77300		<1%	1,731	$115K
J9035	Injection, bevacizumab, 10 mg	<1%	282	$111K
J1930	Injection, lanreotide, 1 mg	<1%	74	$110K
36430		<1%	2,848	$108K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	1,585	$106K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	2,275	$103K
88185		<1%	2,376	$83K
A9585	Injection, gadobutrol, 0.1 ml	<1%	1,466	$79K
78306		<1%	840	$79K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	1,007	$71K
77334		<1%	1,770	$67K
36561		<1%	172	$66K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	2,843	$65K
77387		<1%	835	$64K
70491		<1%	1,839	$60K
J3490	Unclassified drugs	<1%	10,410	$59K
77290		<1%	486	$56K
96523		<1%	3,209	$55K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	4,672	$53K
71250		<1%	1,566	$52K
96401		<1%	2,009	$48K
J8540	Dexamethasone, oral, 0.25 mg	<1%	8,599	$45K
77301		<1%	344	$43K
82565		<1%	6,423	$42K
88321		<1%	3,773	$38K
J9202	Goserelin acetate implant, per 3.6 mg	<1%	476	$38K
76536		<1%	859	$37K
J2704	Injection, propofol, 10 mg	<1%	3,855	$37K
J9395	Injection, fulvestrant, 25 mg	<1%	154	$37K
31575		<1%	1,012	$36K
83735		<1%	13,690	$33K
83615		<1%	15,034	$31K
86900		<1%	3,883	$31K
J9070	Cyclophosphamide, 100 mg	<1%	394	$29K
76642		<1%	693	$28K
81025		<1%	1,430	$28K
82728		<1%	2,825	$27K
96368		<1%	691	$27K
86885		<1%	3,501	$26K
84439		<1%	6,379	$26K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	4,847	$26K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	4,932	$26K
88184		<1%	2,243	$25K
88341		<1%	2,530	$25K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	<1%	100	$24K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	362	$24K
85027		<1%	4,360	$24K
96417		<1%	5,830	$23K
84100		<1%	8,345	$23K
84443	Thyroid stimulating hormone (TSH)	<1%	7,343	$23K
J1170	Injection, hydromorphone, up to 4 mg	<1%	3,061	$22K
J0690	Injection, cefazolin sodium, 500 mg	<1%	2,556	$22K
78816		<1%	78	$22K
88271		<1%	594	$21K
94760		<1%	3,114	$21K
J2997	Injection, alteplase recombinant, 1 mg	<1%	639	$20K
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	1,866	$20K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	503	$20K
86300		<1%	2,571	$19K
J9312	Injection, rituximab, 10 mg	<1%	41	$19K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	2,897	$19K
85610		<1%	6,942	$18K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	4,001	$18K
85730		<1%	6,838	$18K
74183		<1%	228	$17K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	4,188	$17K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,464	$17K
88342		<1%	3,169	$16K
88307		<1%	497	$16K
77049		<1%	81	$16K
84481		<1%	3,539	$15K
81455		<1%	16	$15K
J8501	Aprepitant, oral, 5 mg	<1%	522	$14K
85097		<1%	1,064	$14K
71046	Radiologic examination, chest; 2 views	<1%	1,418	$14K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	2,958	$14K
C1769	Guide wire	<1%	1,279	$13K
82378		<1%	4,609	$13K
A9579	Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	<1%	84	$13K
J9171	Injection, docetaxel, 1 mg	<1%	172	$12K
77062		<1%	428	$12K
J9045	Injection, carboplatin, 50 mg	<1%	1,959	$11K
77001		<1%	893	$11K
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	83	$10K
88264		<1%	678	$10K
77065	Tomosynthesis, mammo	<1%	1,046	$10K
96409		<1%	778	$10K
74160		<1%	504	$10K
A6209	Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing	<1%	437	$10K
96376		<1%	1,115	$10K
80197		<1%	1,720	$10K
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	1,421	$10K
77066	Tomosynthesis, mammo	<1%	988	$10K
77338		<1%	392	$9K
86920		<1%	2,283	$9K
86901		<1%	3,837	$9K
J9190	Injection, fluorouracil, 500 mg	<1%	2,697	$9K
J9267	Injection, paclitaxel, 1 mg	<1%	1,821	$8K
P9037	Platelets, pheresis, leukocytes reduced, irradiated, each unit	<1%	52	$8K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	1,233	$8K
81001		<1%	2,232	$8K
96411		<1%	2,128	$8K
87641		<1%	426	$7K
77061		<1%	189	$7K
82784		<1%	3,601	$7K
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram	<1%	84	$7K
85046		<1%	1,757	$7K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	2,844	$7K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,334	$6K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	1,268	$6K
72197		<1%	46	$6K
77295		<1%	29	$6K
G0378	Hospital observation service, per hour	<1%	423	$6K
86334		<1%	2,600	$6K
Q9969	Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	<1%	1,002	$5K
99152		<1%	1,121	$5K
88311		<1%	1,072	$5K
84165		<1%	2,596	$5K
0399T		<1%	44	$5K
87086	Culture, bacterial; quantitative colony count, urine	<1%	859	$5K
80061	Lipid panel	<1%	1,035	$5K
88237		<1%	753	$5K
71275	Computed tomographic angiography, chest, with contrast material	<1%	29	$5K
88313		<1%	1,193	$5K
76937		<1%	602	$5K
99153	Mod sedat endo service >5yrs	<1%	1,014	$5K
86304		<1%	1,016	$5K
96377		<1%	1,764	$4K
36593		<1%	396	$4K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	210	$4K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	85	$4K
94761		<1%	1,067	$4K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	144	$4K
74178		<1%	85	$4K
84156		<1%	722	$4K
83521		<1%	798	$4K
A6258	Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing	<1%	395	$4K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	612	$4K
88275		<1%	613	$4K
83883		<1%	1,556	$4K
J9206	Injection, irinotecan, 20 mg	<1%	664	$4K
J3480	Injection, potassium chloride, per 2 meq	<1%	492	$3K
88360		<1%	357	$3K
77280		<1%	21	$3K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	43	$3K
80195		<1%	1,370	$3K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	14	$3K
81206		<1%	29	$3K
84550		<1%	1,726	$3K
72156		<1%	24	$3K
85049		<1%	656	$3K
82232		<1%	1,024	$3K
94729		<1%	249	$3K
C9399	Unclassified drugs or biologicals	<1%	291	$3K
72158		<1%	69	$3K
94010		<1%	119	$2K
71045	Radiologic examination, chest; single view	<1%	124	$2K
J0461	Injection, atropine sulfate, 0.01 mg	<1%	184	$2K
88112		<1%	49	$2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	125	$2K
87070		<1%	252	$2K
81003		<1%	640	$2K
86141		<1%	568	$2K
84432		<1%	211	$2K
87040		<1%	268	$2K
87497		<1%	471	$2K
97161		<1%	45	$2K
93356		<1%	668	$2K
36590		<1%	14	$2K
0002A		<1%	273	$2K
86301		<1%	1,409	$2K
82803		<1%	17	$2K
88172		<1%	133	$2K
94726		<1%	248	$2K
93971		<1%	62	$2K
87340		<1%	620	$2K
81450		<1%	25	$2K
86355		<1%	242	$1K
77370		<1%	44	$1K
84153		<1%	727	$1K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	124	$1K
82607		<1%	870	$1K
0099U		<1%	100	$1K
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	780	$1K
83540		<1%	1,214	$1K
86803		<1%	567	$1K
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	42	$1K
J7999	Compounded drug, not otherwise classified	<1%	232	$1K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,588	$1K
84166		<1%	395	$1K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	288	$1K
82533		<1%	463	$1K
83550		<1%	988	$1K
86704		<1%	221	$1K
0001A		<1%	255	$1K
83036	Hemoglobin; glycosylated (A1C)	<1%	767	$1K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	222	$986.91
74170		<1%	47	$982.79
86335		<1%	334	$956.21
77085		<1%	28	$929.12
84484		<1%	273	$922.77
83970		<1%	154	$912.05
94642		<1%	27	$894.02
87486		<1%	194	$869.15
J3489	Injection, zoledronic acid, 1 mg	<1%	275	$842.97
87581		<1%	194	$838.52
A6402	Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing	<1%	61	$835.82
86357		<1%	242	$770.20
86356		<1%	240	$770.20
86800		<1%	212	$762.51
86359		<1%	206	$759.68
97802		<1%	50	$758.75
A4216	Sterile water, saline and/or dextrose, diluent/flush, 10 ml	<1%	122	$749.48
86360		<1%	206	$721.57
82746		<1%	475	$695.70
88173		<1%	258	$669.29
81378		<1%	16	$616.59
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	158	$616.19
86140		<1%	354	$599.74
83690		<1%	542	$588.78
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	92	$568.91
90472	Immunization administration, each additional vaccine (list separately)	<1%	106	$511.52
88300		<1%	12	$494.00
85651		<1%	512	$468.95
84403		<1%	364	$460.11
88108		<1%	44	$451.90
87205		<1%	37	$434.56
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	98	$415.51
82105		<1%	207	$396.65
86644		<1%	87	$391.58
A9561	Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries	<1%	746	$378.76
0011A		<1%	304	$364.83
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	152	$363.41
77470		<1%	19	$300.42
82024		<1%	126	$299.16
81268		<1%	26	$263.67
88161		<1%	52	$254.99
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	118	$235.66
83520		<1%	558	$228.50
73552		<1%	17	$225.63
83880		<1%	50	$189.60
93702		<1%	13	$162.20
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	103	$154.68
82248		<1%	20	$139.39
82977		<1%	40	$132.14
C1788	Port, indwelling (implantable)	<1%	103	$105.51
J9060	Injection, cisplatin, powder or solution, 10 mg	<1%	100	$102.47
C1729	Catheter, drainage	<1%	16	$100.34
86592		<1%	27	$91.37
96040		<1%	12	$87.89
83010		<1%	88	$87.14
0012A		<1%	219	$46.54
82570		<1%	18	$43.28
0013A		<1%	38	$40.00
J0780	Injection, prochlorperazine, up to 10 mg	<1%	46	$38.00
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	174	$35.88
88177		<1%	37	$35.40
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	108	$34.00
83605		<1%	110	$32.25
J0640	Injection, leucovorin calcium, per 50 mg	<1%	234	$29.58
84702		<1%	12	$18.14
87799		<1%	16	$16.49
90686		<1%	179	$14.32
84145		<1%	34	$11.63
85652		<1%	35	$10.56
89051		<1%	18	$10.08
87077		<1%	30	$9.28
36600		<1%	17	$4.34
83001		<1%	15	$4.05
82150		<1%	16	$3.13
G0008	Administration of influenza virus vaccine	0%	18	$0.00
0064A		0%	17	$0.00
J2060	Injection, lorazepam, 2 mg	0%	27	$0.00
72157		0%	18	$0.00
87186		0%	16	$0.00
J9000	Injection, doxorubicin hydrochloride, 10 mg	0%	98	$0.00
90670		0%	87	$0.00
0003A		0%	96	$0.00
90746		0%	13	$0.00
A6403	Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing	0%	16	$0.00
J9370	Vincristine sulfate, 1 mg	0%	38	$0.00
J1644	Injection, heparin sodium, per 1000 units	0%	42	$0.00
90648		0%	13	$0.00
A6250	Skin sealants, protectants, moisturizers, ointments, any type, any size	0%	18	$0.00
76942		0%	19	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSINGH, SARABDEEP (EXECUTIVE VP COO)